Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.42 |
| ▸ | TRPC7 | Q9HCX4 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135281 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL20135642 | 0.94 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL20135209 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL20135602 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL20135132 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL20135129 | 0.77 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL17672421 | 0.75 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL19732302 | 0.73 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL19461439 | 0.72 | GRIN2B (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL30773875 | 0.71 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | SMN1; SMN2 2532/4885NPC1 4881/4885RAB9A 270/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | SMN1; SMN2 2476/4885NPC1 4882/4885RAB9A 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.